Trial Profile
A Phase 1/2 Study of the Concomitant Administration of Indoximod Plus Immune Checkpoint Inhibitors for Adult Patients With Advanced or Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Jun 2020
Price :
$35
*
At a glance
- Drugs Indoximod (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors NewLink Genetics Corporation
- 03 Jun 2020 Status changed from active, no longer recruiting to completed.
- 01 Oct 2018 According to a NewLink Genetics Corporation media release, biomarker data from this trial will be presented at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting.
- 03 Jul 2018 Status changed from recruiting to active, no longer recruiting.